Enza Montemitro
Overview
Explore the profile of Enza Montemitro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allegretta C, Montemitro E, Ciciriello F, Altieri M, Sabbioni G, Breveglieri G, et al.
Cell Immunol
. 2025 Jan;
409-410:104926.
PMID: 39837005
Background: Lungs of people with Cystic Fibrosis (pwCF) are characterized by chronic inflammation and infection with P. aeruginosa. High levels of IL-17 A and F have been observed in sputum...
2.
Rossitto M, Fox V, Vrenna G, Tuccio Guarna Assanti V, Essa N, Lepanto M, et al.
Microorganisms
. 2024 Oct;
12(10).
PMID: 39458360
Cystic fibrosis (CF) is a life-threatening genetic disease characterised by chronic lung infections sustained by opportunistic pathogens such as During the chronic long-lasting lung infections, adapts to the host environment....
3.
De Marchis M, Montemitro E, Boni A, Federici A, Di Giovanni D, Cristiani L, et al.
Ital J Pediatr
. 2024 Jan;
50(1):6.
PMID: 38233941
Background: Multiple Breath washout (MBW) represents an important tool to detect early a possible pulmonary exacerbation especially in Cystic Fibrosis (CF) disease. Lung clearance index (LCI) is the most commonly...
4.
Graziano S, Boldrini F, Pellicano G, Milo F, Majo F, Cristiani L, et al.
Chest
. 2023 Nov;
165(4):800-809.
PMID: 37925143
Background: Italy initiated elexacaftor/tezacaftor/ivacaftor (ETI) for people with cystic fibrosis (pwCF) in July 2021. It has led to dramatic improvements in lung function, BMI, sweat chloride, and respiratory symptoms. However,...
5.
Pariano M, Puccetti M, Stincardini C, Napolioni V, Gatticchi L, Galarini R, et al.
Am J Respir Cell Mol Biol
. 2022 Oct;
68(3):288-301.
PMID: 36252182
Hypoxia contributes to the exaggerated yet ineffective airway inflammation that fails to oppose infections in cystic fibrosis (CF). However, the potential for impairment of essential immune functions by HIF-1α (hypoxia-inducible...
6.
Montemari A, Manco M, Fiocchi A, Bartoli M, Facchiano F, Tabolacci C, et al.
J Inflamm Res
. 2022 Oct;
15:5677-5685.
PMID: 36238762
Objective And Design: Cystic fibrosis-related diabetes (CFRD) is a severe complication associated with increased morbidity and mortality in cystic fibrosis (CF) patients. Extensive inflammatory state in CF leads to pancreas...
7.
Rossitto M, Tabarini P, Tuccio Guarna Assanti V, Montemitro E, Pompilio A, Fiscarelli E
Int J Environ Res Public Health
. 2021 Feb;
18(3).
PMID: 33525434
Living with cystic fibrosis (CF) exposes patients to the risk of developing anxiety and depression, with therapeutic compliance reduction, hospitalization increase, and quality of life and health outcomes deterioration. As...
8.
Cesaro S, Pegoraro A, Sainati L, Lucidi V, Montemitro E, Corti P, et al.
J Pediatr
. 2020 Feb;
219:196-201.e1.
PMID: 32037152
Objective: To describe the hematologic outcome and long-term survival of patients enrolled in the Shwachman-Diamond syndrome Italian Registry. Study Design: A retrospective and prospective study of patients recorded in the...
9.
Montuschi P, Lucidi V, Paris D, Montemitro E, Shohreh R, Mores N, et al.
Front Pharmacol
. 2018 Jul;
9:595.
PMID: 29967580
15-F-Isoprostane, a reliable biomarker of oxidative stress, has been found elevated in exhaled breath condensate (EBC), a non-invasive technique for sampling of airway secretions, in patients with cystic fibrosis (CF)....
10.
Gillioen B, Plancoulaine S, Montemitro E, Flori S, Lin J, Guyon A, et al.
Early Hum Dev
. 2017 Sep;
115:46-50.
PMID: 28892739
No abstract available.